Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Long-Term Investments came in at $27.3 million in Q1 2026, up 12.71% YoY from $24.2 million in Q1 2025, and up 21.08% on a QoQ basis from $22.5 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 6 years of Long-Term Investments data on file, last reported at $27.3 million in Q1 2026.
- Quarterly Long-Term Investments rose 12.71% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.3 million (up 12.71% YoY) and the FY2025 annual result came in at $22.5 million, up 4.51% from the prior year.
- Long-Term Investments climbed to $27.3 million in Q1 2026, from $22.5 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $27.3 million in Q1 2026 to a low of $12.9 million in Q3 2023.
- A 4-year average of $19.0 million and a median of $19.2 million in 2025 frame the typical range for Long-Term Investments.
- The widest YoY moves for Long-Term Investments: up 62.47% in 2025, down 4.51% in 2025.
- Tracing CPRX's Long-Term Investments over 4 years: stood at $16.5 million in 2023, then jumped by 30.78% to $21.6 million in 2024, then increased by 4.51% to $22.5 million in 2025, then grew by 21.08% to $27.3 million in 2026.
- The last three Long-Term Investments figures came in at $27.3 million (Q1 2026), $22.5 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 27.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.29 Mn |
| Dec 31, 2025 | 22.54 Mn |
| Sep 30, 2025 | 19.17 Mn |
| Jun 30, 2025 | 21.26 Mn |
| Mar 31, 2025 | 24.21 Mn |
| Dec 31, 2024 | 21.56 Mn |
| Sep 30, 2024 | 14.84 Mn |
| Jun 30, 2024 | 13.08 Mn |
| Mar 31, 2024 | 15.35 Mn |
| Dec 31, 2023 | 16.49 Mn |
| Sep 30, 2023 | 12.90 Mn |
| Sep 30, 2019 | 5.01 Mn |
| Jun 30, 2019 | 5.01 Mn |
| Mar 31, 2019 | 4.99 Mn |
| Dec 31, 2018 | 5.01 Mn |
| Sep 30, 2018 | 5.02 Mn |
| Jun 30, 2018 | 5.01 Mn |